Home - Products - Others - Other Targets - Capitatin 3-O-β-D-glucopyranosyl-7-O-α-L-rhamnopyranoside

Capitatin 3-O-β-D-glucopyranosyl-7-O-α-L-rhamnopyranoside

CAS No. ———

Capitatin 3-O-β-D-glucopyranosyl-7-O-α-L-rhamnopyranoside( ——— )

Catalog No. M38448 CAS No. ———

Capitatin 3-O-β-D-glucopyranosyl-7-O-α-L-rhamnopyranoside

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
25MG Get Quote Get Quote
50MG Get Quote Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Capitatin 3-O-β-D-glucopyranosyl-7-O-α-L-rhamnopyranoside
  • Note
    Research use only, not for human use.
  • Brief Description
    Capitatin 3-O-β-D-glucopyranosyl-7-O-α-L-rhamnopyranoside
  • Description
    Capitatin 3-O-β-D-glucopyranosyl-7-O-α-L-rhamnopyranoside
  • In Vitro
    ———
  • In Vivo
    ———
  • Synonyms
    ———
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ———
  • Research Area
    ———
  • Indication
    ———

Chemical Information

  • CAS Number
    ———
  • Formula Weight
    ———
  • Molecular Formula
    ———
  • Purity
    >98% (HPLC)
  • Solubility
    ———
  • SMILES
    ———
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • 2-Acetyl-4-butyramid...

    Gray crystalline powder.

  • KL044

    KL044 is a cryptochrome 1 (CRY1) activator that prolongs circadian rhythms and inhibits PER2 activity. KL044 inhibits melanogenesis by inhibiting the cAMP/PKA/CREB pathway.

  • Somatostatin-28 a

    Somatostatin-28 (sheep, human rat mouse) is a biologically active polypeptide, synthesised in the proximal intestinal epithelial cells. Somatostatin-28 (sheep, human rat mouse) suppresses glucose-stimulated insulin secretion without affecting circulating basal insulin concentration. Somatostatin-28 (sheep, human rat mouse) also targets to somatostatin receptor subtype 5 (SSTR5) to regulate GLP-1 secretion.